

RESEARCH ARTICLE

Functional characterization of the HMP-P synthase of *Legionella pneumophila* (Lpg1565)

Michael D. Paxhia ¹ | Michele S. Swanson ² | Diana M. Downs ¹

¹Department of Microbiology, University of Georgia, Athens, GA, USA

²Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA

Correspondence

Diana M. Downs, Department of Microbiology, University of Georgia, Athens, GA 30606, USA.
Email: dmdowns@uga.edu

Funding information

National Institute of General Medical Sciences, Grant/Award Number: GM095837; Division of Graduate Education, Grant/Award Number: DGE-1443117

Abstract

The production of the pyrimidine moiety in thiamine synthesis, 2-methyl-4-amino-5-hydroxymethylpyrimidine phosphate (HMP-P), has been described to proceed through the Thi5-dependent pathway in *Saccharomyces cerevisiae* and other yeast. Previous work found that ScThi5 functioned poorly in a heterologous context. Here we report a bacterial ortholog to the yeast HMP-P synthase (Thi5) was necessary for HMP synthesis in *Legionella pneumophila*. Unlike ScThi5, LpThi5 functioned in vivo in *Salmonella enterica* under multiple growth conditions. The protein LpThi5 is a dimer that binds pyridoxal-5'-phosphate (PLP), apparently without a solvent-exposed Schiff base. A small percentage of LpThi5 protein co-purifies with a bound molecule that can be converted to HMP. Analysis of variant proteins both in vivo and in vitro confirmed that residues in sequence motifs conserved across bacterial and eukaryotic orthologs modulate the function of LpThi5.

Importance: Thiamine is an essential vitamin for the vast majority of organisms. There are multiple strategies to synthesize and salvage this vitamin. The predominant pathway for synthesis of the pyrimidine moiety of thiamine involves the Fe-S cluster protein ThiC. An alternative pathway utilizes Thi5, a novel enzyme that uses PLP as a substrate. The Thi5-dependent pathway is poorly characterized in yeast and has not been characterized in Bacteria. Here we demonstrate that a Thi5-dependent pathway is necessary for thiamine biosynthesis in *Legionella pneumophila* and provide biochemical data to extend knowledge of the Thi5 enzyme, the corresponding biosynthetic pathway, and the role of metabolic network architecture in optimizing its function.

KEYWORDS

HMP, Hydroxymethyl pyrimidine, *Legionella pneumophila*, lpg1565, THI5, Thiamine synthesis

1 | INTRODUCTION

Thiamine pyrophosphate (TPP), the active form of Vitamin B₁, is a cofactor important for several enzymes in central metabolism including transketolase, pyruvate dehydrogenase, and α -ketoglutarate dehydrogenase. The cofactor is comprised of two moieties, 2-methyl-4-amino-5-hydroxymethylpyrimidine diphosphate (HMP-PP) and 4-methyl-5- β -hydroxyethylthiazole phosphate (THZ-P), that are

independently synthesized and combined to form TPP (Jurgenson et al., 2009). The pyrimidine precursor HMP-P is synthesized from an intermediate in the purine biosynthetic pathway (aminoimidazole ribotide) by the phosphomethylpyrimidine synthase ThiC (E.C. 4.1.99.17) an enzyme encoded in plants, archaea, and most bacteria (Jurgenson et al., 2009). However, some organisms, notably *Saccharomyces cerevisiae*, use Thi5 (HMP-P synthase) in place of ThiC to generate HMP-P. Labeling studies showed that the atoms of

HMP originate from histidine and a B6 vitamer, presumably pyridoxal-5'-phosphate (PLP) (Ishida et al., 2008; Tazuya et al., 1989; 1995). (Figure 1a) The hemiascomycetes clade of fungi contain multiple paralogs of *THI5*, and genetic studies in *S. cerevisiae* S288c showed any member of the *THI5/11/12/13* gene family was sufficient for the synthesis of HMP-P (Wightman and Meacock, 2003). Other fungi encode a single ortholog of *THI5*, and a *Schizosaccharomyces pombe* mutant lacking the *THI5* homolog *nmt1* is a thiamine auxotroph that specifically requires HMP for growth (Maudrell, 1990; Schweingruber et al., 1991).

The Thi5 HMP-P synthase from lower eukaryotes (e.g., *Candida albicans* and *S. cerevisiae*) is a member of the periplasmic-binding protein superfamily (COG0715), and three-dimensional crystal structures of these proteins have been solved (Coquille et al., 2012; Lai et al., 2012), and are available in protein databases (PDBs 4H65, 4H67, 4H6D, 4ESX). The *S. cerevisiae* Thi5 protein was purified with PLP in its active site and formed dimers in solution, an oligomeric state confirmed by its crystal structure (Coquille et al., 2012). An in vitro study of the *C. albicans* Thi5 protein showed that the protein had HMP-P synthase activity, albeit unexpectedly low. When PLP and iron were provided in a reaction mixture, *Ca*Thi5 produced

between 0.2 and 0.5 mol of HMP-P per mol of protein (Lai et al., 2012). The small amount of product formed, in addition to the lack of the stimulation of enzyme activity by histidine, suggested that a necessary molecule was supplied by the protein. *Ca*Thi5 variants H66G and H66N had no activity in the in vitro assay (Lai et al., 2012), and other variants that altered residue H66 were inactive in vivo (Coquille et al., 2012). In total, the data led authors of one study with *Ca*Thi5 to conclude that the enzyme used a suicide mechanism to donate a moiety of residue H66 to yield HMP-P (Lai et al., 2012). The in vitro formation of HMP-P required a high concentration (600 μ M) of *Ca*Thi5, the addition of excess ferrous iron (900 μ M), and molecular oxygen (Lai et al., 2012). The above conditions of the assay, and the low product yield achieved, make it formally possible that a component or condition relevant for Thi5 activity in vivo was not recapitulated in the in vitro work.

Despite the presumed in vivo availability of both histidine and pyridoxine substrates, *Sc*Thi5 fails to support the growth of a *thiC* mutant of *S. enterica* on minimal glucose medium (Palmer et al., 2015). The ease with which suppressors that restored growth were isolated suggested that the architecture of the metabolic network was impacting Thi5 activity. An additional study found that the




FIGURE 1 Pathways for HMP-P, PLP biosynthesis. (a) Two biosynthetic routes for the synthesis of thiamine pyrophosphate (TPP) are schematically represented with a focus on the source of HMP-P. Gene products are indicated by the reactions they catalyze. Those depicted in blue are present in *S. enterica* and not *L. pneumophila*. Those in red, are found in *L. pneumophila* and other organisms as described in the text. In *S. enterica*, ThiC converts 5'-aminoimidazole ribotide (AIR) into HMP-P, while Thi5 synthesizes HMP-P from histidine and a B₆ vitamer. Incorporation of atoms derived from histidine and the B₆ vitamer into HMP-P are shown (Ishida et al., 2008; Tazuya et al., 1989; 1995). (b) Two pathways for PLP biosynthesis are schematically represented with emphasis on the final steps. Enzymes belonging to the DXP-dependent pathway are highlighted in red and exemplified by *S. enterica*. PdxH is present in many organisms as part of a salvage pathway and its presence does not indicate the DXP-dependent pathway is present. The enzymes of the DXP-independent pathway are highlighted in green and exemplified by *S. cerevisiae* (Snz/Sno) and *B. subtilis* (PdxS/PdxT). (c) Organization of the thiamine biosynthetic locus in *L. pneumophila*. The putative annotations and locus tags for coding regions homologous with other thiamine biosynthetic enzymes are shown. The TPP riboswitch in the 5'-UTR of *lpg1565* is indicated (Sahr et al., 2017). AHAP, 3-amino-1-hydroxyacetone phosphate; AIR, 5'-aminoimidazole ribotide; DXP, deoxyxylulose-5-phosphate; G3P, glyceraldehyde-3-phosphate; Gln, glutamine; HMP, 2-methyl-4-amino-5-hydroxymethylpyrimidine; HMP-P, 4-amino-5-hydroxymethylpyrimidine phosphate; HMP-PP, 4-amino-5-hydroxymethylpyrimidine diphosphate; PNP, pyridoxine-5'-phosphate; PLP, pyridoxal-5'-phosphate; R5P, ribose-5'-phosphate; THZ, 4-methyl-5- β -hydroxyethylthiazole; THZ-P, 4-methyl-5- β -hydroxyethylthiazole phosphate; Thi, thiamine; TPP, thiamine diphosphate; TMP, thiamine phosphate

Thi5-dependent thiamine synthesis in *S. cerevisiae* required an ammonium-dependent PLP synthase (E.C. 4.3.3.6; SNZ2, SNZ3) (Paxhia and Downs, 2019). Thus, it was formally possible that the lack of activity in a bacterial host reflected the need for a PLP synthesis/delivery system specific for the Thi5 enzyme. Such enzymes are not present in *S. enterica*, which generates PLP via a DXP-dependent pathway (Figure 1b). The study herein was initiated to address this possibility and to better understand the cellular function and biochemical properties of a bacterial Thi5 protein. To gain insight into the impact of network structure on thiamine synthesis, we identified and focused on a *THI5* homolog encoded within the *Legionella pneumophila* thiamine biosynthesis operon (Rodionov et al., 2002; Sahr et al., 2012). This homolog is regulated by a thiamine-pyrophosphate riboswitch in the 5' untranslated region, and a study in *L. pneumophila* Paris demonstrated that transcription from this region is repressed by thiamine-pyrophosphate and activated by CsrA (Sahr et al., 2017). The work herein verified the role of *lpg1565* (redesignated *thi5*) in thiamine synthesis in *L. pneumophila* and analyzed its ability to function in *S. enterica*. Further, data herein showed that *LpThi5* co-purifies with a molecule that can be converted to HMP, and identified variants that have altered activity in vivo. In total, this work expands our understanding of the function of Thi5, and its integration in the metabolic network of the cell.

2 | RESULTS AND DISCUSSION

2.1 | *THI5* orthologs co-occur with DXP-dependent PLP synthesis in prokaryotes

In order to test the simple hypothesis that lack of Thi5 function in *S. enterica* was due to an absence of an *Snz/PdxS* pathway for PLP biosynthesis, genomes in the IMG database containing *THI5* orthologs were found using iterative BLAST-P searches, and the phylogeny of those homologs, as well as the presence of homologs of key PLP biosynthetic genes, were assessed. A CCCXC motif distinguishes *ScThi5p* from the structural homolog *N*-formyl-4-amino-5-aminomethyl-2-methylpyrimidine-binding *ThiY*, and so this motif was used to identify putative *THI5* homologs that had been annotated as a substrate-binding protein for an ABC transport system (Bale et al., 2010). Bacterial homologs with the CCCXC motif were identified in the *Endozoicomonas*, *Fluorobacter*, and *Legionella* genera. Orthologs identified without the N-terminal 60 amino acids were not considered, since this region of the protein contains residues important for coordinating PLP in the *ScThi5p* active site (Coquille et al., 2012). Presence of homologs for PNP synthase (*PdxJ*; E.C. 2.6.99.2), or a subunit of the glutamine-hydrolyzing PLP synthase (*PdxS*, *Snz*; E.C. 4.3.3.6) were used to define the presence of the DXP-dependent or -independent pathway for PLP biosynthesis, respectively (Figure 2). Among Eukaryotes *THI5* homologs were only found in fungi. Each of the 180 fungal genomes with a putative *THI5* gene had a homolog of both *pdxS* and *pdxH*, indicating that they used the DXP-independent pathway for PLP biosynthesis and could salvage B_6 vitamers, similar

to *S. cerevisiae*. Two clades of γ -proteobacteria with *THI5* homologs were identified: four *Endozoicomonas* species and 31 species within the Legionellaceae family. Each of these bacteria had homologs to *pdxJ* and *pdxH* indicating the synthesis of PLP was by the DXP-dependent pathway and suggesting a potential for vitamer salvage. It was noted that many of the Legionellaceae species contained multiple paralogs of *pdxH* (29 of 31 species have 2-4 paralogs), a feature that was not investigated further. Thus, genomic analysis suggested *Thi5* enzymes could function in the absence of a *PdxS* PLP synthase. While this finding appeared to negate the hypothesis that *ScThi5* required this enzyme as a specific PLP delivery system to function in vivo, it is worth noting that non-orthologous replacement for *PdxS* was not ruled out by these analyses.

2.2 | *lpg1565* encodes a Thi5 ortholog and contributes to HMP synthesis in *L. pneumophila*

A role for the *THI5* ortholog in a metabolic network using DXP-dependent PLP biosynthesis was investigated using *L. pneumophila*. *lpg1565* is adjacent to several open reading frames predicted to encode enzymes for thiamine biosynthesis. The operon includes homologs of *thiO*, *thiG*, and *thiF* (*lpg1566*, *lpg1567*, *lpg1569*, respectively), and a short ORF with homology to *thiS*. Each of these proteins is involved in the synthesis of the thiazole moiety of thiamine in defined pathways. The operon also had an ORF homologous to a fusion protein between *thiD2* and *thiE* (*lpg1568*) (Figure 1c) (Sahr et al., 2012). A mutant of *L. pneumophila* with an in-frame insertion-deletion of *lpg1565* was constructed and subjected to growth analyses. The Δ *lpg1565* strain with an empty vector (pJB98) required exogenous thiamine for growth on Modified Ristroph Medium (Figure 3a). A plasmid containing the *lpg1565* gene (pDM1631) was unable to complement the nutritional requirement of the Δ *lpg1565* strain, suggesting the insertion was polar on one or more downstream genes (data not shown). A plasmid carrying the entire locus (*lpg1565* – *lpg1569*; pDM1632) restored the growth of the Δ *lpg1565* strain in the absence of thiamine (Figure 3b). In contrast, a plasmid derived from pDM1632 that lacked *lpg1565* (pDM1633) failed to complement the nutritional defect of the Δ *lpg1565* strain. Full growth of the Δ *lpg1565* strain carrying pDM1633 was restored by the addition of 100 nM thiamine. Partial growth of this strain was restored with the addition of 2.5 mM HMP (Figure 3c). Together these results demonstrate that *L. pneumophila* requires the *lpg1565* gene product for thiamine biosynthesis, specifically to generate the pyrimidine moiety. Based on these data and the bioinformatic analyses, *lpg1565* was renamed *thi5*, and the gene product designated *LpThi5* throughout.

The inability of HMP to restore robust growth to the *thi5* mutant suggested *L. pneumophila* lacked the salvage system characterized in *E. coli*, *S. enterica* and *S. cerevisiae*. In these organisms, exogenous HMP is incorporated into the biosynthetic pathway by the hydroxymethylpyrimidine kinase *ThiD* (E.C. 2.7.1.49). The presence of a *thiD2-thiE* fusion homolog (*lpg1568*) in *L. pneumophila*, rather than full-length *thiD* and *thiE* genes is likely to be the genomic difference




FIGURE 2 Phylogeny of Thi5 homologs and associated PLP biosynthetic pathways. The phylogenetic relationship of Thi5p homologs among Bacteria (blue lines) and select Eukaryotes (red lines) in the IMG database containing the CCCXC motif. Annotated KEGG functions for *pdxJ* (K03474; E.C. 2.6.99.2) and *pdxS* (K06215; E.C. 4.3.3.6) in each genome are highlighted. Organisms in which mutants lacking the homolog are demonstrable HMP auxotrophs are highlighted in bold. Organisms that contain multiple Thi5 homologs are annotated with an asterisk. The scale represents percent genetic distance between homologs [Colour figure can be viewed at wileyonlinelibrary.com]




FIGURE 3 *lpg1565* contributes to HMP synthesis in *L. pneumophila*. A mutant of *L. pneumophila* with an insertion-deletion of *lpg1565* containing (a) pJB98 (vector only), (b) pDM1632 (pJB98-*lpg1565-9*), or (c) pDM1633 (pJB98-*lpg1566-9*) was grown on MRM supplemented with (i) no additions, (ii) HMP (2.5 mM) or (iii) thiamine (100 nM) as indicated. Error bars indicate the standard deviation of three independent biological replicates

that accounts for the weak HMP salvage observed. Other ThiD2-ThiE fusion proteins lack the HMP kinase activity associated with purified full-length ThiD, while retaining HMP-P kinase activity. Thus, a non-specific kinase may generate some HMP-P from exogenous HMP, allowing salvage via Lpg1568 in *L. pneumophila* (Thamm et al., 2017). The ability to salvage thiamine reflects the presence of a homolog to a thiamine pyrophosphokinase (E.C. 2.7.6.2; ThiN) in *L. pneumophila* (Lpg2497), although a transporter for thiamine has not been identified.

2.3 | *LpThi5* functions in the *S. enterica* metabolic network

The co-occurrence phylogenetic data above was not consistent with the simple hypothesis that Thi5 proteins require an Snz/PdxS-like protein to be functional. However, the phylogeny of Thi5 proteins clustering with distinct PLP biosynthesis pathways may suggest distinct structural features have evolved in Thi5 orthologs within metabolic networks of similar architecture. Therefore, we considered whether there were structural aspects of Thi5 that differ in concordance with the pathway for PLP biosynthesis in the organism and whether structural differences could account for functional differences in vivo. As a first step, the functional complementation of a *thiC* mutant of *S. enterica* with a protein from a Eukaryote (*ScThi5p*) and the ortholog from a Prokaryote (*LpThi5*) were compared. *ScTHI5* was codon-optimized for expression in *S. enterica* and cloned into pTac85 under the regulation of a Tac promoter (pDM1625). *Lpthi5* was similarly inserted into pTac85 to generate pDM1486. Both constructs were introduced into a *thiC* mutant of *S. enterica*, and growth was monitored on several carbon sources to test the response to different metabolisms (Figure 4). Neither *Lpthi5* nor *ScTHI5* restored growth on any carbon source without induced expression of the respective genes. However, when transcription was induced with IPTG (100 μ M), *Lpthi5* (pDM1486) allowed

the *S. enterica* mutant to grow on ribose, glucose, gluconate, and galactose (Figure 4, Panel I, a–d). In contrast, the codon-optimized *ScTHI5* conferred growth on ribose but not glucose and supported intermediate growth on gluconate and galactose (Figure 4, Panel II, e–h).

When the thiazole moiety THZ (100 nM) was added to the growth medium, expression of *ScTHI5* allowed full growth of the *thiC* mutant on glucose, galactose, and gluconate, and also increased the growth conferred by *Lpthi5*. Titration experiments on glucose medium showed the addition of THZ reduced the HMP concentration required for full growth of a *thiC* mutant from 25 nM to 10 nM (Supplemental Table 1). The growth stimulation by THZ is likely due to the kinetics of thiamine synthase (ThiE), which allows excess THZ-P to drive the reaction when HMP-PP levels are low (Backstrom et al., 1995). Additionally, the *thiC* mutant required less HMP when using ribose as a carbon source than when growing on glucose, also considered to be an indirect effect of metabolic flux differences (Supplemental Table 1). In total, the data above support the conclusion that *LpThi5* is an HMP-P synthase that is more active in the *S. enterica* metabolic network than is the *ScThi5* enzyme.

2.4 | *LpThi5* is a pyridoxal-5'-phosphate-binding protein

LpThi5-His₆ was purified from *E. coli* and characterized for quaternary structure and cofactor occupancy, using size exclusion chromatography and UV-Vis spectroscopy, respectively. Based on protein standards of known molecular weight, *LpThi5* was calculated to be 86 ± 5.8 kDa, reasonably close to the theoretical weight of a *LpThi5* dimer (72.2 kDa) (Figure 5) and thus consistent with the designation of *ScThi5p* as a dimer based on size exclusion chromatography as well as its crystal structure (Coquille et al., 2012).

After purification in buffer lacking PLP, *LpThi5* had absorbance maxima at 325 and 425 nm, features that are characteristic of a




FIGURE 4 *LpThi5* can generate HMP in *S. enterica*. Strains of *S. enterica* lacking *thiC* and containing either *Lpthi5* (Panel I) or a codon-optimized version of *ScTHI5* (Panel II) were grown on a minimal medium containing either 11 mM glucose (a and e), 13.2 mM ribose (b and f), 11 mM galactose (c and g) or 11mM gluconate (d and h). Medium was otherwise supplemented with nothing (open circles), 100 μ M IPTG (solid squares), 100 μ M IPTG and 100 nM THZ (solid inverted triangles) or 100 nM thiamine (solid circles). Growth was measured by optical density at 650 nm over time. Error bars indicate the standard deviation of three independent biological replicates

TABLE 1 Plasmids, bacterial strains, and primers used in this study

Plasmid name	Description
pDM1486	pTac85- <i>lpg1565</i>
pDM1625	pTac85- <i>ScTHI5</i> (codon-optimized)
pDM1630	pET28b- <i>lpg1565</i> -His ₆
pJB98	Amp ^R Thy ⁺ (Hammer and Swanson, 1999)
pDM1631	pJB98- <i>lpg1565</i>
pDM1632	pJB98- <i>lpg1565-69</i>
pDM1633	pJB98- <i>lpg1566-69</i>
Strain	Genotype
<i>S. enterica</i>	
DM15269	Δ <i>thiC1225</i> Δ <i>araCBAD</i> / pDM1486
DM16449	Δ <i>thiC1225</i> Δ <i>araCBAD</i> / pDM1625
<i>L. pneumophila</i>	
DMLp6	<i>thyA rpsL hsdR lpg1565::Cm</i> / pJB98
DMLp7	<i>thyA rpsL hsdR lpg1565::Cm</i> / pDM1632
DMLp8	<i>thyA rpsL hsdR lpg1565::Cm</i> / pDM1633
Primer name	Sequence
LpTHI5 NcoI F	TAGGCCATGGCGATGTCATCACTAAAATCC
LpTHI5 Sall R	TAGGGTCGACTTAATTTTCAAGACAACAGGCCG
LpTHI5-HisTag Sall R	TAGGGTCGACTTAGTGATGGTGATGGTGATGATTTTCAAGACAACAGGCCG
LpTHI5 K66A F	<u>tgcaacagatgaatcattgccgcaacaccgaaatctactgttcccagg</u>
LpTHI5 H70A	<u>ttttgctttggctgcaacagtagcaatcattgctttaacaccgaaatc</u>
LpTHI5 C191A	<u>cgatcaattagctggtttaggcgtgtgtttctgctcaatacaa</u>
LpTHI5 C192A	<u>cgatcaattagctggtttaggcgtgtgtttctgctcaatacaatttatt</u>
LpTHI5 C193A	<u>tcaattagctggtttaggcgtgtgtctttctgctcaatacaatttattgtt</u>
LpTHI5 C195A	<u>ctggtttaggcgtgtgtttgcttcctcaatacaatttattgttcctga</u>
LpTHI5 G118A	<u>ggaaacgagtaggttatatcgccgaattcgcaaaaaaattat</u>
LpTHI5 E119A	<u>gaaacgagtaggttatatcgccgattcgcaaaaaaattattgatg</u>
LpTHI5 F120A	<u>aataattttttgccgcttcgccaatataacctactgctttccaaca</u>
LpTHI5 G121A	<u>gtaggttatatcgccgaattcgcaaaaaaattattgatgattgg</u>
LpTHI5 C191S	<u>cgatcaattagctggtttaggcagctgtgtttctgctcaatacaa</u>
LpTHI5 C192S	<u>cgatcaattagctggtttaggcgtgtgtttctgctcaatacaatttatt</u>
LpTHI5 C193S	<u>tcaattagctggtttaggcgtgtgtcttctgctcaatacaatttattgtt</u>
LpTHI5 C195S	<u>ctggtttaggcgtgtgttttcagctcaatacaatttattgttcctga</u>
LpTHI5 C191H	<u>cgatcaattagctggtttaggccattgtgtttctgctcaatacaa</u>
LpTHI5 C192H	<u>cgatcaattagctggtttaggcgtgtcattgtttctgctcaatacaatttatt</u>
LpTHI5 C193H	<u>tcaattagctggtttaggcgtgtgtcatttctgctcaatacaatttattgtt</u>
LpTHI5 C195H	<u>ctggtttaggcgtgtgttttcattcaatacaatttattgttcctga</u>
<i>lpg1565</i> F	AAATTAAGCGGAATCGAAGTG TAGC
<i>lpg1565</i> R	AAATATGAGGTAAAAATTTCCAGGTCT
<i>lpg1565</i> P0	TTTAAATAATAACATAAGGAGTTATGGCGATGTCATGTGTAGGCTGGAGCTGCTTC
<i>lpg1565</i> P2	AATGCCTGCTGCCATAATTAATTTTCAAGACAACAGCATATGAATATCCTCCTTAGTTC
<i>lpg1565</i> comp F (BamHI)	AAAGGATCCCCTCCATATATCCAATCTCGCAAG
<i>lpg1565</i> comp R (SacI)	AAAGAGCTCCCAGCATTATGTAATACAAAAGCCA
<i>thiOperon_fw</i> d	attcttcgagctcggtagccCTCCATATATCCAATCTC
<i>thiOperon_rev</i>	gtcgactctagaggatcccTATCTGCTAAATAATATTGCCG
NEBQC- <i>thi</i> OF	ATGCGAGCAGGCATTGTA
NEBQC- <i>thi</i> 5R	AACTCCTTATGTTATTATTTTAAATATTATGGAG

Note: Underlining designates nucleotides encoding six additional histidine residues at the c-terminus.




FIGURE 5 *LpThi5* is dimeric in solution. The oligomeric state of *LpThi5* in solution was determined by size exclusion chromatography. An SEC 650 column was equilibrated with 50 mM HEPES + 1 mM TCEP, pH 7.5. Molecular weight standards or *LpThi5* (50 μ l) were injected and eluted at a flow rate of 1 mL/min. (a) Aliquots (50 μ l) of thyroglobuline (670 kDa), γ -globulin (158 kDa), ovalbumin (44 kDa), and myoglobin (17 kDa) were used as size standards to generate the standard curve and interpolate the size of *LpThi5*. The position of *LpThi5* is represented by a square. (b) Absorbance (280 nm) was followed over 20 ml of elution buffer after *LpThi5* was injected on the column. The lone peak eluted at 13 ml




FIGURE 6 *LpThi5* purifies with pyridoxal-5'-phosphate. Recombinant *LpThi5*-His₆ was purified, a portion of the protein preparation was dialyzed against HEPES (50 mM, pH 7.5) containing PLP (200 μ M) and TCEP (1 mM) at 4°C overnight. Unbound PLP was removed using a PD-10 desalting column, and both preparations were characterized by UV-visible spectroscopy. Three spectra were taken of 100 μ M *LpThi5* (a), *LpThi5* + PLP (b) and *LpThi5*_{H70A} + PLP (c), untreated (solid line), treated with 25 mM NaBH₄ (dotted line), treated with 0.1 M NaOH (dashed line)

tautomeric equilibrium of the Schiff-base of characterized PLP-binding proteins (Mozzarelli and Bettati, 2006) (Figure 6a). Dialysis of *LpThi5* against HEPES buffer (50 mM, pH 7.5) containing PLP (200 μ M) increased the absorbance maxima at 325 and 425 nm, indicating the as-purified protein was not fully occupied with PLP (Figure 6b). Denaturation of *LpThi5* (100 μ M in 200 μ l) with NaOH (0.1 M), released PLP that was detected by the absorption maximum at 392 nm, characteristic of free PLP in HEPES (Geders et al., 2012). The PLP occupancy of the as-purified protein was $29 \pm 1\%$, while dialysis against PLP-containing buffer raised the occupancy to $63 \pm 2\%$.

In a majority of PLP-binding proteins, treatment with NaBH₄ (1 mM) reduces the Schiff-base between the protein and PLP, resulting in a noticeable reduction in absorbance at 425 nm (Soniya and Chandra, 2018; Toney, 2011). Treatment of as-purified *LpThi5* with up to 25 mM NaBH₄ did not affect the absorbance at 425 nm.

Accordingly, if present, a Schiff-base between PLP and the protein was not solvent accessible (Figure 6a). Surprisingly, when a variant lacking the proposed catalytic residue H70 (*LpThi5*_{H70A}) was treated with NaBH₄ (25 mM), absorbance at 425 nm decreased significantly (Figure 6c). These data suggested the catalytic histidine residue might shield access to the Schiff base in the wild-type protein.

2.5 | *LpThi5* purifies with a bound metabolite

Efforts to detect HMP-forming activity of *LpThi5* with the addition of its presumed substrates, histidine and PLP (Ishida et al., 2008; Tazuya et al., 1995) under multiple conditions were not successful. Specifically, these conditions included incubations of 100 μ M *LpThi5* at 37°C for 16 hr in 50 mM HEPES pH 7.5, aerobically or anaerobically, with the addition of 1-10X histidine, PLP or PLP + histidine. However,

control experiments generated an unexpected result. When *LpThi5* (20 nmol) in HEPES (50 mM, pH 7.5) was incubated overnight (16 hr) at 37°C, a biologically active compound was released when the protein was denatured with heat (Figure 7a). The biologically active molecule allowed the growth of a *thiC* mutant, but not a *thiI* mutant strain of *S. enterica*; moreover, this activity was detected in samples with no added substrate. Based on these data the compound was not thiamine, which would have satisfied the requirement of both the *thiC* and the *thiI* mutants. Further, neither histidine, PLP, or histidine and PLP together detectably impacted the biological activity present after the incubation described (data not shown).

A series of experiments identified conditions required for the production of the biologically active compound. First, if a protein sample was pre-treated with acid (10% TFA), base (0.1 M NaOH), or temperature (95°C, 5 mins) prior to incubation at 37°C, (i.e., T = 0),

no biological activity was detected. These data demonstrated that time was required for formation, and that HMP was not present in the purification. Second, when the concentration of HEPES was 10, rather than 50 mM, no biological activity was detected. Third, the formation of a biologically active molecule was dependent on buffer: Tris (40 mM, pH 7.5), Bis-Tris-Propane (40 mM, pH 7.5), or HEPES resulted in its formation, but incubation in MOPS (40 mM, pH 7.5) did not. Additionally, since the protein sample was exchanged into a buffer lacking PLP using a PD10 desalting column, the relevant molecule was likely bound to the enzyme. In total, these data suggested the molecule that purified with the protein was not the fully formed biologically active compound. It is formally possible that the protein is partially modified *in vivo*, and that this modified *LpThi5* may serve as the substrate for the *in vitro* reaction as previously proposed for *CαThi5* (Lai et al., 2012).




FIGURE 7 Purified *LpThi5* releases HMP. (a) *LpThi5* protein in buffer was denatured with heat before incubation (T = 0), and after overnight incubation (O/N). In each case the supernatant spotted on a lawn of a *thiC* mutant of *S. enterica* embedded in soft agar is shown. HMP was spotted as a control. Growth was detected as turbidity after 16 hr incubation at 37°C. (b) *LpThi5* (0.75 mg) was incubated overnight in buffer (black line) or not (hashed line) before denaturing protein at 95°C for 5 min. The supernatants were injected onto an HPLC and absorbance was monitored over time at 270 nm. The star indicates the peak that contained activity in the overnight sample, and the inset shows the UV-Vis spectrum of this peak. (c) MALDI-TOF of authentic HMP-P, the biologically active, and the inactive fractions from *LpThi5* samples described are shown. (d) Impact of iron in the buffer bioassay for the production of HMP(-P) after a 4 hr incubation with iron

2.6 | HMP is released after the incubation of Thi5

The bioassay results indicated that the active compound released from *LpThi5* was either HMP, HMP-P or a molecule that the *S. enterica* could transport and convert to HMP-P. Indeed, MALDI-TOF MS identified the active molecule as HMP (Figure 7). The molecule released after an overnight incubation of 690 nmol of *LpThi5* was concentrated with a C18 SepPak and separated by HPLC with a Luna C₁₈ column. Fractions (0.5 ml) were collected across 30 min. From a sample incubated overnight, biological activity was found in fractions with a retention time of 20–21.5 min and the corresponding peak had UV-Vis spectral features similar to HMP. Moreover, a standard of authentic HMP eluted at a similar retention time. A control (T = 0) sample generated no peak with a UV-Vis spectrum consistent with HMP(-P); nor did these collected fractions have biological activity (Figure 7b). The active fractions of the sample from an overnight incubation contained a mass of 140.0 Da when ionized by MALDI-TOF MS. This peak, present in the active but not an inactive fraction, was consistent with the monoisotopic mass of ionized HMP (Figure 7c). Together these data support the conclusion that *LpThi5* co-purified with a molecule that generated HMP upon incubation in buffer. It was considered possible the relevant molecule was HMP-P since it was not clear the phosphorylated form would be stable during the ionization protocol.

2.7 | Iron decreases the time required for the release of HMP(-P) from *LpThi5*

Initial experiments suggested that more than 12-hour incubation was needed to generate detectable HMP from a purified Thi5 protein. Based on its putative metal-binding motif (CCCXC) (Bale et al., 2010), we tested the hypothesis that the reaction is catalyzed by metals. To do so, purified Thi5 was pre-incubated with a 10-fold excess of a series of metals, and reaction time was quantified. *LpThi5* samples supplemented with metals were denatured after 8 hr at 37°C and product formation was determined by bioassay. Of the metals tested (Mg²⁺, Ni²⁺, Mn²⁺, Zn²⁺, Co²⁺, Ca²⁺, Cd²⁺, Cu²⁺, and Fe), only Fe stimulated the release of HMP by *LpThi5*. The presence of either Fe (III) or Fe (II) salts increased the efficiency of HMP formation with *LpThi5*. Titration of 100 μM protein with 50, 100, 200, 500 μM, or 1 mM iron showed that a Fe:protein ratio of 2:1 was optimal for product formation. When *LpThi5* (100 μM) and iron ammonium sulfate (200 μM) were present in buffer, HMP was detectable by bioassay after 2 hr at 37°C. In these conditions, HMP release increased over time plateauing at 4 hr at a level similar to that released with an overnight incubation in buffer alone (Figure 7d). Based on the ability of iron to increase the rate of product release, it was plausible that the generation of HMP in an overnight incubation was facilitated by iron that was in the *LpThi5* protein preparation and was acting as a general electron sink. The requirement for buffer suggests that the exchange of ions between the protein and the solvent, perhaps accelerated by iron, could be important for the release of HMP. Bound iron in purified *LpThi5* was quantified by Ferene assay (Kennedy


et al., 1984; Palmer and Downs, 2013). A sample of *LpThi5* (70.8 μM) contained 545 ± 43 nM Fe, while a buffer-only control contained 140 nM Fe. These data indicated that 18 nmol *LpThi5* contained only 0.10 ± 0.008 nmol of Fe, minimizing the possibility that iron was specifically bound to the purified protein. While not quantifiable precisely, analysis by bioassay suggested 5%–8% of purified *LpThi5* protein released HMP. The stoichiometry of HMP(-P) to *LpThi5* cannot effectively distinguish between the release of a previously bound molecule and the suicide mechanism that was previously suggested (Lai et al., 2012).

2.8 | Conserved residues are involved in the function of *LpThi5* in vivo and in vitro

Thi5 variants that have individually altered conserved residues were surveyed for their functional properties. Previous work with *ScThi5* showed alanine substitutions at the PLP-binding lysine residue binding (K62) or the adjacent histidine residue (H66) eliminated function in vivo (Coquille et al., 2012). Likewise, neither *LpThi5*_{K66A} or *LpThi5*_{H70A} complemented a *thiC* strain of *S. enterica* (data not shown). Further, these purified variants did not produce a biologically active compound when incubated in the presence of iron (data not shown). Previous work with *ScThi5* showed that alanine substitutions in the CCCXC motif compromised function in vivo (Coquille et al., 2012). To corroborate the importance of this motif in *LpThi5*, each of the cysteines in the conserved CCCXC motif was changed to Ala, His or Ser by site-directed mutagenesis in pDM1486. None of the 12 variants of *LpThi5* complemented a *thiC* mutant when tested only with ribose as the sole carbon source (data not shown). Further, four of the variants (*LpThi5*_{C191A}, *LpThi5*_{C192A}, *LpThi5*_{C193A}, *LpThi5*_{C195A}) were purified, and none released a biologically active molecule after a 4 hr incubation in the presence of iron, or overnight in its absence, implying that these conserved residues are essential for Thi5 activity in vitro and in vivo (data not shown).

The crystal structure of *ScThi5p* revealed a GEFG motif involved in hydrogen bonding with the phosphate group of PLP in the active site (Coquille et al., 2012). This motif is strictly conserved between diverse homologs of Thi5 (Figure S2) and was modeled in *LpThi5* (Figure 8b). Because of the conservation of this motif as well as residues lining the active site across Bacteria and Eukaryotes (K66, H70 in *LpThi5*) it is highly likely the proteins have the same mechanism. If the mechanism proposed for *CaThi5* is correct, it would suggest H70 was a substrate for *LpThi5*. *LpThi5* variants of the GEFG loop were tested for activity in vivo. A G121A variant failed to complement an *S. enterica thiC* mutant grown with glucose or ribose as a carbon source. However, when the expression of this protein was induced, the variant was not soluble, suggesting that the alanine substitution of the G121 residue impacted the folding of *LpThi5*. Interestingly, alleles of *LpThi5* encoding individual alanine substitutions in each position of the GEF motif supported the growth of the *thiC* mutant on ribose medium (Figure 9a–c) but eliminated complementation on glucose (Figure 9d–f). Taken together with previous results demonstrating

FIGURE 8 *LpThi5* and *ScThi5p* share structural motifs in the active site. (a) Amino acid sequences of *LpThi5* and *ScThi5p* were aligned by CLUSTAL Omega (Sievers et al., 2011), similar residues are highlighted in grey and identical residues are highlighted in black. Conserved residues interrogated in this study are boxed. (b) A structural homology model was generated with Phyre2 (Kelley et al., 2015), and residues in the CCCXC motif or those predicted to coordinate PLP in the active site are modeled as sticks (K66, H70, G118, E119, F120) and visualized with PyMOL



a reduced requirement for HMP on ribose compared to glucose (Table S1), the data suggest that these variants had reduced activity in vivo. When overexpressed and purified, both *LpThi5*_{G118A} and *LpThi5*_{F120A} variants produced products that supported the growth of an HMP auxotroph when incubated in buffer with iron (data not shown). These data indicated that both *LpThi5*_{G118A} and *LpThi5*_{F120A} variants co-purified with the same molecule as wild-type *LpThi5*, consistent with the detection of the enzyme's in vivo activity.

2.9 | Conclusions

Prior to this work, the Thi5 pathway for the synthesis of HMP was characterized only in fungi. The data herein show that *L. pneumophila* encodes a Thi5 pathway for HMP-P synthesis but lacks an efficient salvage pathway for HMP. *LpThi5* appears to outperform the *S. cerevisiae* Thi5 ortholog in the heterologous metabolic network of *S. enterica*, even when the fungal locus was codon optimized for expression in this host. These differences may suggest structural variances within the PLP biosynthetic pathways of fungi versus bacteria. When

purified, *LpThi5*-His6 binds PLP, but the histidine residue in the active site restricts the solvent accessibility of the Schiff base. *LpThi5* purifies with a molecule that when incubated with iron produces HMP. Neither the identity of this molecule nor the formal possibility that it is a partially modified His70 residue was addressed here. We identified a conserved GEF motif that modulates function in vivo and corroborated the importance of other conserved amino acids predicted to be in the active site for the function of this homolog both in vitro and in vivo (CCCXC, K66, H70). The results herein extend the understanding of the Thi5 pathway for HMP-P synthesis and confirm its presence beyond Eukaryotes into the Legionellaceae family of Bacteria.

3 | EXPERIMENTAL PROCEDURES

3.1 | Strains

Strains used in this study are derivatives of strain *Salmonella enterica* Serovar Typhimurium strain LT2, *Escherichia coli* K12, or *Legionella pneumophila* strain Lp02. Strains, plasmids, and their source are listed




FIGURE 9 *Lpthi5* variants have a reduced ability to complement *thiC* mutant on glucose. Strains of *S. enterica* lacking *thiC* and containing a plasmid expressing *Lpthi5* alleles encoding *LpThi5*_{G118A} (a and d), *LpThi5*_{E119A} (b and e), or *LpThi5*_{F120A} (c and f) under the regulation of P_{tac} were grown on a minimal medium. Panels a-c contained ribose (13.2 mM) as a carbon source, while panels d-f contained glucose (11 mM) as a carbon source. In each case, the medium included no additions (open circles), 100 μ M IPTG (solid squares) or 100 nM thiamine (solid circles). Growth was determined by following optical density at 650 nm over time. Error bars indicate the standard deviation of three independent biological replicates

in Table 1. An *lpg1565* deletion mutant in *L. pneumophila* strain Lp02, a thymidine auxotroph derived from Philadelphia-1 (Berger and Isberg, 1993), was constructed by recombineering as described previously (Bryan et al., 2013). In brief, the *lpg1565* gene and its ~750 bp 5' and 3' flanking sequences were amplified using primers *lpg1565F* and *lpg1565R* (Table 1). The DNA product was cloned by standard methods into vector pGEM T-easy (Promega), creating pGEM-*lpg1565*. An *FRT*-flanked *cat* cassette encoding chloramphenicol resistance was amplified from pKD3 (Datsenko and Wanner, 2000) using primers *lpg1565P0* and *lpg1565P2* (Table 1), and the product purified. Replacement of the *lpg1565* allele with the *cat* cassette was accomplished by co-transforming *E. coli* strain DY330, which encodes λ -red recombinase, by electroporation with the purified *cat* fragment and pGEM-*lpg1565*. Candidate *E. coli* DY330 colonies harboring pGEM-*lpg1565::cat* were screened by PCR, and the corresponding recombinant plasmids then transformed into *E. coli* DH5 α . Next, the recombinant allele *lpg1565::cat* was amplified by PCR using primers *lpg1565F* and *lpg1565R* (Table 1) and transferred to *L. pneumophila* strain Lp02 by natural transformation and chloramphenicol selection. Replacement of the Lp02 *lpg1565* locus with *cat* was confirmed by DNA sequencing.

3.2 | Media and chemicals

E. coli and *S. enterica* strains were routinely grown on Nutrient Broth (NB) containing 8 g/L of Difco Nutrient broth and 5 g/L of NaCl. For protein purification the cultures were grown in superbroth (SB; 32 g/L of vegetable tryptone, 20 g/L of yeast extract (Fisher Scientific), 5 g/L of

NaCl with 0.05 N NaOH). Solid media contained 1.5% agar. Kanamycin (Kn) and Ampicillin (Ap) were added to rich media at 50, or 100 mg/L, respectively. Minimal media was No-carbon E salts (NCE) (Vogel and Bonner, 1956) with 1 mM $MgSO_4$, 0.1X trace minerals (Balch et al., 1979), and 11 mM glucose, gluconate, galactose or 13.2 mM ribose as a sole carbon source as indicated. 2-methyl-4-amino-5-hydroxymethylpyrimidine (HMP) was purchased from LabSeeker, Inc. (Wujiang City, China).

L. pneumophila strains were grown in ACES-buffered Feeley Gorman (FG) broth (10 g/L of ACES, 17.5 g/L of Casein enzymatic hydrolysate, 3 g/L of Beef extract, 0.4 g/L of L-cysteine $HCl \cdot H_2O$, 0.25 g/L of ferric pyrophosphate, adjusted to pH 6.9 with KOH), and on ACES-buffered Yeast Extract plates containing 10 g/L of ACES, 10 g/L of yeast extract, 0.4 g/L of L-cysteine $HCl \cdot H_2O$, 0.25 g/L of ferric pyrophosphate, adjusted to pH 6.9 with KOH, 1.7% agar and 0.2% activated charcoal (Feeley et al., 1978; Pasculle et al., 1980). Defined media for growth of *L. pneumophila* was Modified Ristroph Medium (MRM) (Ristroph et al., 1981; Sauer et al., 2005). 100 μ g/ml thymidine was added to all media when growing thymine auxotrophs. When divalent cations were present in the incubation of *LpThi5*, they were added as the following salts; $MgSO_4$, $NiSO_4$, $MnCl_2$, $ZnSO_4$, $CoCl_2$, $CaCl_2$, $CdCl_2$, $CuSO_4$, $Fe(II)(NH_4)_2(SO_4)_2$, $Fe(III)_2(SO_4)_3$. Chemicals were purchased from Sigma-Aldrich, St. Louis, MO unless otherwise indicated.

3.3 | Growth analysis

Growth of bacterial strains was monitored at OD_{650} in a 96-well plate with a BioTek ELx808 plate reader. For *L. pneumophila*, strains

were grown overnight in ACES-buffered FG (5 ml) to an $OD_{650} = 1.5$ (late-log) and pelleted ($9,400 \times g$ for 5 min). The cell pellet was resuspended in an equal volume of ddH_2O and used to inoculate (5%) MRM medium with indicated supplements. Plates were incubated at $37^\circ C$ with fast shaking, and data were plotted using Prism 7 (Graph Pad). *S. enterica* strains were grown overnight in NB Ap (2 ml) prior to pelleting and resuspension in an equal volume of 0.85% NaCl. The cell suspension was used to inoculate (1%) the indicated medium. Plates were incubated at $37^\circ C$ with medium shaking, and data were plotted using Prism 7 (Graph Pad).

3.4 | Bioinformatics analyses

A BLAST-P search of the RefSeq Protein database (September 20, 2019) used the amino acid sequence encoded by *lpg1565* as a query. The default BLAST parameters were used, and the top 1,000 hits were examined. Bacterial homologs with a conserved CCCXC motif were identified in the *Endozoicomonas*, *Fluorobacter*, and *Legionella* genera. Based on this result, finished and permanent draft genomes on the IMG database of *Endozoicomonas*, *Fluorobacter* and *Legionella* genera of Bacteria and all available Eukaryotic genomes were queried to find *THI5* homologs (Chen et al., 2019). Iterative BLAST-P searches using the default settings and the predicted amino acid sequences of *THI5* homologs from *L. pneumophila* (*lpg1565*), *Endozoicomonas elysicola* (B144DRAFT_03762), and *S. cerevisiae* (*THI5*; YFL058W) as the query identified 587 genomes that contained *THI5* homologs with a CCCXC motif. The amino acid sequences of the 35 non-redundant bacterial *THI5* homologs were downloaded from the IMG database in FASTA format, and the headers of the files were modified to place the organism name first. Representative eukaryotic homologs from *S. cerevisiae* and *S. pombe* were also included in the phylogenetic analysis. Geneious Prime 2019.2.1 was used to align these 41 homologs. A MUSCLE Alignment with 100 iterations was used to generate a PHYLIP alignment file which was analyzed via Smart Model Selection PhyML to generate a phylogenetic tree using the Le-Gascuel (LG) substitution model (Edgar, 2004; Guindon et al., 2010; Lefort et al., 2017). The phylogenetic tree was annotated using the interactive Tree Of Life (iTOL) and Adobe Illustrator (Letunic and Bork, 2019). The presence or absence of homologs of genes encoding key enzymes involved in PLP biosynthesis and salvage (*pdxJ*, *pdXS*, and *pdXH*) were identified using the IMG Pathway Profile for the 215 non-redundant genomes with *THI5* homologs (Chen et al., 2019). In cases where multiple genomes were found within the same species, only genomes from the original type strain were used to annotate putative PLP biosynthesis homologs.

3.5 | Molecular techniques

Plasmids were constructed and modified using standard molecular techniques. pTac85 (Marsh, 1986), pJB98 (Hammer and Swanson, 1999), and pET-28b(+) (Novagen) were isolated using the PureYield Plasmid Miniprep System (Promega, Madison, WI). Q5 DNA

polymerase (New England Biolabs, Ipswich, MA) was used to amplify DNA with primers synthesized by Integrated DNA Technologies, Coralville, IA or Eton Bioscience, Inc., Research Triangle Park, NC. PCR products were purified using the PCR purification kit (Qiagen, Venlo, Limburg, The Netherlands). Restriction endonucleases and ligase were purchased from New England Biolabs, Ipswich, MA.

The *THI5* homolog *lpg1565* was amplified by PCR with *L. pneumophila* gDNA as a template using primers LpTHI5 NcoI F and LpTHI5 Sall R, listed in Table 1. The amplified product was purified, digested with NcoI and Sall, and ligated into pTac85 (Marsh, 1986), resulting in pDM1486, which was confirmed by sequencing. The *lpg1565* coding sequence was cloned with additional nucleotides encoding a C-terminal His₆ tag into the NcoI/Sall sites of pTac85. The relevant insert was then cloned into pET-28b(+) at the NcoI/Sall sites to generate plasmid pDM1630, which expressed LpThi5-His₆ fusion protein for purification. ScTHI5, with flanking NcoI and Sall sites, was codon-optimized for translation in *E. coli*, purchased from GenScript and ligated into pTac85 to generate pDM1625. Primers for site-directed mutagenesis were designed using the Agilent QuikChange Primer Design webtool and are listed in Table 1. Variants were created following instructions from the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA), and confirmed by sequencing (Eton Bioscience, Inc, Research Triangle Park, NC).

To construct pDM1631, the *lpg1565* locus was amplified by PCR from gDNA using primers *lpg1565* comp F and *lpg1565* comp R (Table 1). The fragment was purified, digested with BamHI and SacI, and ligated into pJB98. The *lpg1565-lpg1569* genes that constitute an operon (Sahr et al., 2012) were PCR amplified with gDNA as a template, using primers ThiOperon_Fwd and ThiOperon_Rev (Table 1). The amplified product was purified, digested with KpnI and XbaI, and ligated into pJB98 to generate pDM1632. The cloned operon was modified to remove *lpg1565* using the Q5 Site-directed mutagenesis kit (New England Biolabs, Ipswich, MA) with primers NEBQC-thiOF and NEBQC-thi5R (Eton Bioscience, Inc, Research Triangle Park, NC). This manipulation placed the starting codon for *lpg1566* where the annotated starting codon for *lpg1565* is found and generated pDM1633, which was confirmed by sequencing.

3.6 | Protein purification

A culture (100 ml) of *E. coli* BL21-AI carrying pDM1630 was grown overnight at $30^\circ C$ in NB Kn, and four flasks of 1.5 L of SB Kn + pyridoxine (1 mM) were inoculated (1%). Each of four cultures was grown at $37^\circ C$ with shaking (200 rpm). When the OD_{650} reached 0.6, temperature was lowered to $22^\circ C$ and arabinose and IPTG were added to a final concentration of 0.2% and 1 mM, respectively. Incubation continued for 19–20 hr prior to harvesting by centrifugation. Typical cell yield was 8 g/L under these conditions. Hundred grams of cells were resuspended to a total volume of 200 ml in Buffer A [50 mM HEPES (Fisher Scientific), 300 mM NaCl, 20 mM imidazole (Fisher Scientific), 1 mM TCEP (Gold Biotechnology), pH 7.5 at $4^\circ C$] with

DNase (0.025 mg/ml), lysozyme (1 mg/ml) and phenylmethylsulfonyl fluoride (0.1 mg/ml) and incubated on ice for 1 hr. The cell suspension was lysed at 20 kpsi using a Constant Systems Limited One Shot (United Kingdom), and cell lysate was cleared at $48,000 \times g$ (50 min, 4°C). The cell-free extract was passed through a 0.45 μM PVDF filter (Millipore) and injected onto two pre-equilibrated 5 ml of HisTrap HP Ni-Sepharose columns connected in sequence. The protein was washed with five column volumes of Buffer A, five column volumes of 4% Buffer B (Buffer A + 480 mM Imidazole (Fisher Scientific), pH 7.5 at 4°C), and finally eluted from the column with a gradient of Buffer B from 4% to 100% over 10 column volumes. Fractions containing LpThi5 as determined by SDS-PAGE were combined and concentrated by centrifugation using a 10 kDa filter (Millipore), exchanged into 50 mM HEPES buffer with 10% glycerol, 1 mM TCEP, pH 7.5, using a PD10 column following the manufacturer's instructions (GE Healthcare), flash-frozen in liquid nitrogen and stored at -80°C until use. Protein concentration was determined by the extinction coefficient using the theoretical molecular weight and A_{280} extinction coefficient of LpThi5-His₆ as determined by the ExPASy ProtParam database ($\epsilon_{280} = 30,870 \text{ M}^{-1} \text{ cm}^{-1}$) (Gasteiger et al., 2003). A typical purification yielded LpThi5-His₆ that was >85% pure as determined by densitometry (Figure S1).

3.7 | Determination of PLP and iron content

The PLP was released from LpThi5 by denaturing the protein. Fifteen nmol of LpThi5 at a purity of 95% was treated in 50 mM HEPES, pH 7.5 with 0.1 M NaOH in a total volume of 150 μl , the protein removed using a Nanosep 10 kDa spin-filter (PALL), and the absorbance of the supernatant measured at 392 nm. PLP was quantified using the empirically determined extinction coefficient of PLP (ϵ_{392}) of $1.965 \times 10^6 \text{ M}^{-1} \text{ cm}^{-1}$ in 50 mM HEPES pH 7.5. Occupancy was calculated based on the percent purity from the starting protein preparation.

Iron associated with LpThi5 was determined by Ferene assay (Kennedy et al., 1984; Palmer and Downs, 2013). Briefly, purified LpThi5 was concentrated using an Amicon Ultra 0.5 ml 30 kDa desalting filter at $14,000 \times g$ for five minutes and resuspending the concentrated protein with 400 μl of 50 mM HEPES, pH 7.5 treated with 2% Chelex. After three cycles of concentration and dilution with the Chelex-treated HEPES, LpThi5 concentration was determined by the extinction coefficient, $\epsilon_{280} = 30,870 \text{ M}^{-1} \text{ cm}^{-1}$. HCl (0.06 N, 50 μl) was added to 19 nmol LpThi5 in 25 mM HEPES (25 μl) and incubated at 80°C for 10 min. The following were added sequentially with mixing by vortex between additions: 0.96 M ammonium acetate (125 μl), 0.2 M ascorbic acid (25 μl), 87 mM SDS (25 μl), and 30 mM Ferene (25 μl). Precipitated protein was removed by centrifugation at $9,000 \times g$ for 5 min and absorbance of the supernatant was measured at 593 nm. Iron content was determined based on the extinction coefficient of Ferene complexed with Fe^{2+} ($\epsilon_{593} = 35.5 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$).

3.8 | Size exclusion chromatography

The quaternary structure of purified LpThi5 (which released bioactive molecule) was assessed by size exclusion chromatography (Hong et al., 2012). A Bio-Rad NGC Chromatography System with an SEC 650 column (Bio-Rad) was equilibrated with two column volumes of HEPES (50 mM), TCEP (1 mM) pH 7.5 at 4°C. Absorbance at 280 nm was monitored to detect when the protein was eluting. Injection of blue dextran (50 μl , 3 mg/ml) in duplicate with a flow rate of 1 ml/min determined the void volume (V_0) was 8.9 ml. The elution volumes (V_e) of duplicate samples of Bio-Rad Gel Filtration Standards (50 μl) were used to establish a standard curve of $K_{av} (\frac{V_e - V_0}{V_{column} - V_0})$ versus \log_{10} (molecular weight) (Figure 5). Three samples, each containing 17 nmol LpThi5, were injected at a flow rate of 1 ml/min, and the elution volume was used to determine the K_{av} . The molecular size of LpThi5 was determined by interpolation from the standard curve ($K_{AV} = -0.231 \log(MW) + 0.732; R^2 = 0.992$), and standard deviation was determined from the deviation in retention time.

3.9 | Detection of HMP

3.9.1 | Bioassay

Purified LpThi5 (20 nmol) in 200 μl HEPES (50 mM, pH 7.5) was incubated at 37°C. At $T = 0, 4, 16$ hr or indicated time, the sample was shifted to 95°C for 5 min, and denatured protein was pelleted by centrifugation ($17,000 \times g$, 5 min). When indicated, ferrous ammonium sulfate hexahydrate was added to 200 μM in the protein sample. The supernatant was evaluated for its ability to stimulate the growth of a *thiC* or *thil* mutant strain of *S. enterica* on minimal medium. Samples (5 μl) were spotted on soft agar embedded with the relevant mutant strain overlaid on minimal medium. Growth was assessed after ~16 hr incubation at 37°C. A *thil* mutant responds to thiamine, or TPP, while a *thiC* mutant responds to thiamine, TPP, HMP, HMP-P.

3.9.2 | High-Performance Liquid Chromatography (HPLC) and MS

Supernatants judged active and inactive by bioassay were subjected to HPLC, monitoring absorbance at 270 nm, which is a lambda max for HMP. Initial control experiments showed that a peak (270 nm) correlated with a bioactive molecule released from an overnight incubation of 3 mg LpThi5. After a 16 hr incubation of 3 mg LpThi5 at 37°C, supernatant (2 ml) resulting from heat treatment was applied to a C18 Sep-Pak Plus cartridge (Waters) for concentration prior to HPLC analysis. Six cartridges were conditioned using 5 ml of acetonitrile (ACN) followed by 10 ml of 50 mM HEPES, pH 7.5. Five 1 ml fractions were eluted with acetonitrile and collected, evaporated, and tested for biological activity by

bioassay. Biologically active fractions (Fractions 1 and 2 from each column) were combined, evaporated, suspended to a total volume of 0.8 ml in water, and 100 μ l fractions were sequentially injected onto the HPLC. A 3 mg sample of *LpThi5* (T = 0) was treated in parallel. Fractions collected from the C18 Sep-Pak Plus cartridges were dehydrated, resuspended in 100 μ l water, and injected onto the HPLC for analysis.

Concentrated samples were separated by reversed-phase HPLC using a Shimadzu LC20-AT delivery system equipped with a 250 \times 4.6 mm Luna C₁₈ column (Phenomenex). The UV-Vis spectrum was monitored over time using a photodiode array detector (Shimadzu). Samples were eluted with a flow rate of 1 ml/min with a gradient of water and ACN; 100% water for 10 min, a gradient from 0% to 15% ACN over 10 min, and 15% ACN for 10 min. Fractions (0.5 ml) collected over 30 min were dehydrated and resuspended in 50 μ l water. Fractions that contained biological activity were determined by bioassay (spotting 1 μ l onto a soft-agar overlay containing a *thiC* strain as an indicator and observing growth). The relevant fractions, eluting from 19.5 to 22 min, were pooled and analyzed by MALDI-TOF MS. Fractions over the same retention time from control samples, which had no activity in the bioassay, were independently pooled. Concentrated fractions and an HMP-P standard were analyzed by MALDI-TOF MS using a Bruker Autoflex (TOF) mass spectrometer at the Proteomics and Mass Spectrometry facility at UGA. Fractions containing biological activity from 25 mg of *LpThi5* that had been incubated for 16 hr were combined from several HPLC runs to facilitate identification by MALDI-TOF MS.

ACKNOWLEDGMENTS

We thank Thomas Knight for the construction of the *lpg1565* mutant and Vincent Starai for the gift of *Legionella pneumophila* genomic DNA. This work was supported by an award from the competitive grants program at the NIH (GM095837) to DMD and a Graduate Research Fellowship Grant (DGE-1443117) from the NSF to MDP. The authors state that they have no conflicts of interest in presenting this work.

AUTHOR CONTRIBUTIONS

Authors contributed to; (i) the conception or design of the study (MDP, DMD), (ii) the acquisition, analysis, or interpretation of the data (MDP, MSS, DMD) and (iii) writing of the manuscript (MDP, DMD).

DATA AVAILABILITY STATEMENT

The data that supports the findings of this study are available in the supplementary material of this article, and additional information is available upon request from the authors.

ORCID

Michael D. Paxhia  <https://orcid.org/0000-0001-9445-6719>

Michele S. Swanson  <https://orcid.org/0000-0003-2542-0266>

Diana M. Downs  <https://orcid.org/0000-0002-1564-6205>

REFERENCES

- Backstrom, A.D., McMordie, R.A.S. and Begley, T.P. (1995) Biosynthesis of thiamin I: the function of the *thiE* gene product. *Journal of the American Chemical Society*, *117*, 2351–2352.
- Balch, W.E., Fox, G.E., Magrum, L.J., Woese, C.R. and Wolfe, R.S. (1979) Methanogens: reevaluation of a unique biological group. *Microbiological Reviews*, *43*, 260–296.
- Bale, S., Rajashankar, K.R., Perry, K., Begley, T.P. and Ealick, S.E. (2010) HMP binding protein ThiY and HMP-P synthase TH15 are structural homologues. *Biochemistry*, *49*, 8929–8936.
- Berger, K.H. and Isberg, R.R. (1993) Two distinct defects in intracellular growth complemented by a single genetic locus in *Legionella pneumophila*. *Molecular Microbiology*, *7*, 7–19.
- Bryan, A., Abbott, Z.D. and Swanson, M.S. (2013) Constructing unmarked gene deletions in *Legionella pneumophila*. *Methods in Molecular Biology*, *954*, 197–212.
- Chen, I.A., Chu, K., Palaniappan, K., Pillay, M., Ratner, A., Huang, J., et al. (2019) IMG/M vol 5.0: an integrated data management and comparative analysis system for microbial genomes and microbiomes. *Nucleic Acids Research*, *47*, D666–D677.
- Coquille, S., Roux, C., Fitzpatrick, T.B. and Thore, S. (2012) The last piece in the vitamin B1 biosynthesis puzzle: structural and functional insight into yeast 4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate (HMP-P) synthase. *Journal of Biological Chemistry*, *287*, 42333–42343.
- Datsenko, K.A. and Wanner, B.L. (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proceedings of the National Academy of Sciences*, *97*, 6640–6645.
- Edgar, R.C. (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Research*, *32*, 1792–1797.
- Feeley, J.C., Gorman, G.W., Weaver, R.E., Mackel, D.C. and Smith, H.W. (1978) Primary isolation media for Legionnaires disease bacterium. *Journal of Clinical Microbiology*, *8*, 320–325.
- Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R.D. and Bairoch, A. (2003) ExPASy: the proteomics server for in-depth protein knowledge and analysis. *Nucleic Acids Research*, *31*, 3784–3788.
- Geders, T.W., Gustafson, K. and Finzel, B.C. (2012) Use of differential scanning fluorimetry to optimize the purification and crystallization of PLP-dependent enzymes. *Acta Crystallographica Section F Structural Biology and Crystallization Communications*, *68*, 596–600.
- Guindon, S., Dufayard, J.F., Lefort, V., Anisimova, M., Hordijk, W. and Gascuel, O. (2010) New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Systematic Biology*, *59*, 307–321.
- Hammer, B.K. and Swanson, M.S. (1999) Co-ordination of *Legionella pneumophila* virulence with entry into stationary phase by ppGpp. *Molecular Microbiology*, *33*, 721–731.
- Hong, P., Koza, S. and Bouvier, E.S. (2012) Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. *Journal of Liquid Chromatography & Related Technologies*, *35*, 2923–2950.
- Ishida, S., Tazuya-Murayama, K., Kijima, Y. and Yamada, K. (2008) The direct precursor of the pyrimidine moiety of thiamin is not urocanic acid but histidine in *Saccharomyces cerevisiae*. *Journal of Nutritional Science and Vitaminology*, *54*, 7–10.
- Jurgenson, C.T., Begley, T.P. and Ealick, S.E. (2009) The structural and biochemical foundations of thiamin biosynthesis. *Annual Review of Biochemistry*, *78*, 569–603.
- Kelley, L.A., Mezulis, S., Yates, C.M., Wass, M.N. and Sternberg, M.J.E. (2015) The Phyre2 web portal for protein modeling, prediction and analysis. *Nature Protocols*, *10*, 845–858.
- Kennedy, M.C., Kent, T.A., Emptage, M., Merkle, H., Beinert, H. and Munck, E. (1984) Evidence for the formation of a linear [3Fe-4S]

- cluster in partially unfolded aconitase. *Journal of Biological Chemistry*, 259, 14463–14471.
- Lai, R.Y., Huang, S., Fenwick, M.K., Hazra, A., Zhang, Y., Rajashankar, K., et al. (2012) Thiamin pyrimidine biosynthesis in *Candida albicans*: a remarkable reaction between histidine and pyridoxal phosphate. *Journal of the American Chemical Society*, 134, 9157–9159.
- Lefort, V., Longueville, J.E. and Gascuel, O. (2017) SMS: Smart Model Selection in PhyML. *Molecular Biology and Evolution*, 34, 2422–2424.
- Letunic, I. and Bork, P. (2019) Interactive Tree Of Life (iTOL) v4: recent updates and new developments. *Nucleic Acids Research*, 47, W256–W259.
- Marsh, P. (1986) Ptac-85, an *E. coli* vector for expression of non-fusion proteins. *Nucleic Acids Research*, 14, 3603.
- Maudrell, K. (1990) nmt1 of fission yeast. A highly transcribed gene completely repressed by thiamine. *Journal of Biological Chemistry*, 265, 10857–10864.
- Mozzarelli, A. and Bettati, S. (2006) Exploring the pyridoxal 5'-phosphate-dependent enzymes. *The Chemical Record*, 6, 275–287.
- Palmer, L.D. and Downs, D.M. (2013) The thiamine biosynthetic enzyme ThiC catalyzes multiple turnovers and is inhibited by S-adenosylmethionine (AdoMet) metabolites. *Journal of Biological Chemistry*, 288, 30693–30699.
- Palmer, L.D., Paxhia, M.D. and Downs, D.M. (2015) Induction of the sugar-phosphate stress response allows *Saccharomyces cerevisiae* 2-methyl-4-amino-5-hydroxymethylpyrimidine phosphate synthase to function in *Salmonella enterica*. *Journal of Bacteriology*, 197, 3554–3562.
- Pasculle, A.W., Feeley, J.C., Gibson, R.J., Cordes, L.G., Myerowitz, R.L., Patton, C.M., et al. (1980) Pittsburgh pneumonia agent: direct isolation from human lung tissue. *Journal of Infectious Diseases*, 141, 727–732.
- Paxhia, M.D. and Downs, D.M. (2019) SNZ3 encodes a PLP synthase involved in thiamine synthesis in *Saccharomyces cerevisiae*. *G3: Genes, Genomes, Genetics*, 9, 335–344.
- Ristroph, J.D., Hedlund, K.W. and Gowda, S. (1981) Chemically defined medium for *Legionella pneumophila* growth. *Journal of Clinical Microbiology*, 13, 115–119.
- Rodionov, D.A., Vitreschak, A.G., Mironov, A.A. and Gelfand, M.S. (2002) Comparative genomics of thiamin biosynthesis in prokaryotes. New genes and regulatory mechanisms. *Journal of Biological Chemistry*, 277, 48949–48959.
- Sahr, T., Rusniok, C., Dervins-Ravault, D., Sismeiro, O., Coppee, J.Y. and Buchrieser, C. (2012) Deep sequencing defines the transcriptional map of *L. pneumophila* and identifies growth phase-dependent regulated ncRNAs implicated in virulence. *RNA Biology*, 9, 503–519.
- Sahr, T., Rusniok, C., Impens, F., Oliva, G., Sismeiro, O., Coppee, J.Y., et al. (2017) The *Legionella pneumophila* genome evolved to accommodate multiple regulatory mechanisms controlled by the CsrA-system. *PLoS Genetics*, 13, e1006629.
- Sauer, J.D., Bachman, M.A. and Swanson, M.S. (2005) The phagosomal transporter A couples threonine acquisition to differentiation and replication of *Legionella pneumophila* in macrophages. *Proceedings of the National Academy of Sciences*, 102, 9924–9929.
- Schweingruber, A.M., Dlugonski, J., Edenharter, E. and Schweingruber, M.E. (1991) Thiamine in *Schizosaccharomyces pombe*: dephosphorylation, intracellular pool, biosynthesis and transport. *Current Genetics*, 19, 249–254.
- Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., et al. (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Molecular Systems Biology*, 7, 539.
- Soniya, K. and Chandra, A. (2018) Free energy landscapes of prototropic tautomerism in pyridoxal 5'-phosphate schiff bases at the active site of an enzyme in aqueous medium. *Journal of Computational Chemistry*, 39, 1629–1638.
- Tazuya, K., Azumi, C., Yamada, K. and Kumaoka, H. (1995) Pyrimidine moiety of thiamin is biosynthesized from pyridoxine and histidine in *Saccharomyces cerevisiae*. *Biochemistry and Molecular Biology International*, 36, 883–888.
- Tazuya, K., Yamada, K. and Kumaoka, H. (1989) Incorporation of histidine into the pyrimidine moiety of thiamin in *Saccharomyces cerevisiae*. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 990, 73–79.
- Thamm, A.M., Li, G., Taja-Moreno, M., Gerdes, S.Y., de Crécy-Lagard, V., Bruner, S.D., et al. (2017) A strictly monofunctional bacterial hydroxymethylpyrimidine phosphate kinase precludes damaging errors in thiamin biosynthesis. *The Biochemical Journal*, 474, 2887–2895.
- Toney, M.D. (2011) Controlling reaction specificity in pyridoxal phosphate enzymes. *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics*, 1814, 1407–1418.
- Vogel, H.J. and Bonner, D.M. (1956) Acetylornithase of *Escherichia coli*: partial purification and some properties. *Journal of Biological Chemistry*, 218, 97–106.
- Wightman, R. and Meacock, P.A. (2003) The THI5 gene family of *Saccharomyces cerevisiae*: distribution of homologues among the hemiascomycetes and functional redundancy in the aerobic biosynthesis of thiamin from pyridoxine. *Microbiology*, 149, 1447–1460.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Paxhia MD, Swanson MS, Downs DM. Functional characterization of the HMP-P synthase of *Legionella pneumophila* (Lpg1565). *Mol Microbiol.* 2021;115: 539–553. <https://doi.org/10.1111/mmi.14622>